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ABSTRACT
Background: The Effectiveness of Masks to Prevent COVID-19. During the Corona pandemic, masks became a 
very vital tool to prevent the spread of COVID-19. With the importance of using masks to prevent this Coronavirus, 
few circulate are circulating on the market. Like the cheapest and many people use is a cloth mask. However, many 
travelers are still confused about wearing so many variants that sell in the market nowadays. 
Aim: To know the best cover to reduce the probability of COVID 19 accidents among travelers in Indonesia.
Methods: The travelers in Indonesia were asked by questionnaire about the mask chosen, symptoms, and the rapid 
test value.
Result: 70.2% of Indonesian travellers without COVID 19 symptoms still use medical masks to prevent contracting 
the CoV2 virus.
Conclusion: Medical covers are even suitable for use as a means of personal protection for travelers who want to 
travel. Apart from being cheap, these masks are readily available in many shopping centres and are comfortable to 
wear while traveling.
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INTRODUCTION
The use of masks is part of a comprehensive series of prevention 
and control measures that can limit the spread of certain 
respiratory viral diseases, including COVID-19. Veneers can be 
used to protect a healthy person (worn to protect oneself in contact 
with an infected person) or to control sources (worn by an infected 
person to prevent further transmission). This mask is certainly not 
an exaggeration when used by travellers. However, the use of shows 
alone is insufficient to provide an adequate level of protection or 
source control. Therefore, other measures at the individual and 
community level also need to be adopted to reduce respiratory 
viruses, especially for travellers. Whether a mask is used or not, 
adherence to hand hygiene, physical distancing, and other infection 
control (PPI) measures are essential to prevent the transmission of 
COVID-19 between travelers. This study provides information and 
guidance regarding masks in health services for the general public 
and when traveling. The World Health Organization (WHO) has 
developed specific guidelines on IPC strategies in health care [1], 
long-term care facilities (FPJP) [2], and home care [3].
Transmission of COVID-19 while traveling
The spread of the COVID-19 virus is increasingly being understood 
every day. The main characteristic of COVID-19 is respiratory tract 
disease, and the spectrum of this viral infection ranges from people 
experiencing very mild non-respiratory symptoms to severe acute 
respiratory illness, sepsis with organ dysfunction, and death. Some 
infected people report no symptoms at all.
According to current evidence, the spread of the COVID-19 virus 
occurs mainly between people via the droplet route (splashes) from 
the respiratory tract and contact. Droplet transmission occurs 
when a person is in close contact (within 1 meter) with an infected 
person, and there is exposure to respiratory droplets that may be 
infected, for example, through coughing, sneezing, or very close 
contact with the person so that the infectious agent enters through 
these points. Such as the mouth, nose, or conjunctiva (eyes) [4-9]. 
Spread can also occur through forms in the immediate environment 
of an infected person. [10,11].
Therefore, the spread of the COVID-19 virus can occur directly 
through contact with people infected or indirectly through contact 
with direct environmental surfaces or objects used for or by an 
infected person (for example, a stethoscope or thermometer).
In situations where aerosol-generating procedures are carried out, 
airborne (through the air) spread of the COVID-19 virus may occur. 
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The scientific community discusses whether the COVID-19 virus 
can also spread through aerosols without an Aerosol-Generating 
Procedure (AGP).
AGP is still actively researched. So far, some studies have found viral 
RNA in air samples from clinical facilities where AGP has not been 
carried out [12-14], but other reviews have not [10,11,15]. However, 
the presence of viral RNA is not the same as a reproducible and 
infectious virus that can spread and inoculate sufficiently to cause 
an invasive infection. A small number of experimental studies 
conducted in aerobiology laboratories found viral RNA [16] and 
viable virus [17].
Current evidence indicates that most of the transmission of 
COVID-19 occurs from symptomatic persons/symptoms to 
others through close contact when not wearing the proper PPE. 
In symptomatic/symptomatic patients, viral RNA can be detected 
in the sample several weeks after the onset of the disease. Still, in 
mild patients, the live virus is not detected after the 8th day of 
the start of symptoms [18,19], although this period may be longer 
for patients. The seriously ill. However, a more prolonged RNA 
shedding does not necessarily mean continued infectious nature. 
The transmissibility of this virus depends on the amount of live 
virus a person sheds, regardless of whether the person coughs and 
expels droplets, the types of contact they have with other people, 
and the PPI measures followed.
Research on transmission must be interpreted in light of the 
context in which communication occurs. It is possible for the 
news to emerge from an infected person and shed the virus but 
do not have symptoms; this transmission is called presymptomatic 
communication. The incubation period for COVID-19, which is the 
time between exposure to the virus and the appearance of symptoms, 
averages 5-6 days but can be up to 14 days [20,21]. Additionally, 
data shows that some people test positive for COVID-19. Through 
a Polymerase Chain Reaction (PCR) test 1-3 days before showing 
symptoms [22]. Presymptomatic transmission is defined as the 
transmission of the COVID-19 virus from an infected person and 
sheds the virus but has not experienced symptoms. Symptomatic 
people have a higher Viral Load (VL) right on or before the onset 
of symptoms than later during infection [23].
Some people infected with the COVID-19 virus have no symptoms 
at all, although they can shed the virus, which can then be spread to 
others. Recently a systematic review found that the proportion of 
asymptomatic cases ranged from 6% to 41% and gave a combined 
estimate of 16% (12%-20%) [24]. For the most part, there are 
significant limitations on studies that this study includes inadequate 
reporting of symptoms or the absence of sufficient restrictions on 
the signs studied.
The live virus has been isolated from specimens of presymptomatic 
and asymptomatic people, indicating that asymptomatic people can 
spread the virus to others [25]. Thorough studies of transmission 
from asymptomatic persons are difficult. Still, available evidence 
from contact tracing reported by the Member States indicates that 
infected but asymptomatic persons are much less likely to transmit 
the virus than persons with symptoms.
Among the published studies, some describe the incidence of 
transmission from asymptomatic people. [20,24-31] For example, 
among infected but asymptomatic people studied in China, 
evidence suggests that 9(14%) [31] Furthermore, one of the two 
rigorous studies examining secondary case-to-contact transmission 
found no secondary information in 91 out of 9 asymptomatic cases 
[32]. In comparison, another study reported 6.4% of patients were 
associated with secondary details—presymptomatic message [33].
The data available to date regarding persistent infection from 
asymptomatic cases come from a small number of studies with 
a small sample size that may be memory biased. Moreover, the 
possibility of transmission of promise could not be ruled out in 
these studies.
Use of medical masks and respirators for travellers
This section provides evidence-based and consensus-based guidance 
on using medical masks and respirators by travelers wishing to travel 
somewhere. Medical masks are defined as surgical or procedure 
masks that are flat or have creases; this type of cover is fastened 
to the head with a strap around the ears or director or both. Its 
performance characteristics are tested according to a series of 
standardized test methods (ASTM F2100, EN 14683, or equivalent) 
that aim to balance high filtration, adequate breathability, and 
(optionally) fluid penetration resistance. [33,34].
A Filtering Facepiece Respirator (FFR), or a respirator, also provides a 
balance of filtration and breathability; however, a respirator filtered 
0.075 micrometer-sized solid particles, compared to a medical mask 
that filtered 3-micrometer droplets. European FFR, according to 
EN 149 standard, with FFP2 performance filters out at least 94% of 
solid NaCl particles and oil droplets, and US N95 FFR, according 
to NIOSH 42 CFR Part 84, filters at least 95% of NaCl particles. 
The certified FFR also ensures unobstructed breathing with 
maximum inhalation and exhalation resistance. Another critical 
difference is how the filtration is tested; the medical mask filtration 
test is carried out on a mask's cross-section. The FFR is tested for 
the whole surface filtration. Therefore, compared to the medical 
show's concave shape or leaky structure, the layers of the filtration 
material and the FFR shape that ensure the outer edges of the FFR 
seal tightly against the user's face guarantee the filtration as claimed 
when worn. Other requirements for FFR performance include not 
exceeding specific parameters for CO2 accumulation, total inward 
leakage, and rope tension strength [35-37]. Evidence is available in 
the WHO Guidelines regarding the types of respiratory protection 
that travellers should use.
METHODS 
The research method used an online survey of 146 respondents in 
various multicenter health services in Indonesia. With some specific 
questions about COVID-19, here the questionnaire: (Table 1).
Table 1: Questionnaires about traveler's masks that used in covid-19 era.
No Questions Answers
1
Have you contacted a COVID-19 positive patient or 
in the same room or connection within 1 meter in 
the last 14 days?
Yes No
2
Have you been to or lived in a country or area where 
COVID-19 is endemic in the past 14 days?
Yes No
3
Have you had a fever (body temperature over 38 
degrees Celsius) or a history of fever or acute 
respiratory infection in the last 14 days?
Yes No
4 Have you had a cough in the last 14 days? Yes No
5 Have you had a cold in the last 14 days? Yes No
6 Have you had shortness of breath in the last 14 days? Yes No
7 Have you had diarrhea in the last 14 days? Yes No
8
Have you ever had a positive rapid test for Covid 19, 
either IgM or IgG?
Yes No
3
Utami AT, et al. OPEN ACCESS Freely available online
J Vaccines Vaccin, Vol. 11(7) No: 1000437
infection. The authors also give massages for all the travelers to 
read doa that Prophet Muhammad SAW tells us.
If someone comes out of the traditional house, then he reads the 
prayer above, then it is conveyed to him: 'You are given directions, 
you are provided for, and you are protected. Instantly the demons 
moved away. Then one demon involving information. How 
could you possibly interfere with someone who has been guided, 
provided, and protected? “(Narrated by Abu Daud 5095, Turmudzi 
3426, and al-Albani declared)”.
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